Celsus Therapeutics Plc. (CLTX) 5.30 $CLTX
Inflammatory Bowel Disease - Pipeline Review, H1 2014: 73 Companies and 135 Drugs Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/rmqbbx/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - ASKA Pharmaceutical Co., Ltd. - ActogeniX NV - Addex Therapeutics - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - AlbireoPharma - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Antibe Therapeutics, Inc. - Aquinox Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Athersys, Inc. - Atlantic Healthcare Limited - Axxam SpA - Basilea Pharmaceutica AG - BioLineRx, Ltd. - Biotec Pharmacon ASA - Boehringer Ingelheim GmbH - Catabasis Pharmaceuticals, Inc. - Celsus Therapeutics Plc - ChironWells GmbH - Complix NV - Compugen Ltd. - Creabilis SA - Delenex Therapeutics AG - Eisai Co., Ltd. - Emergent BioSolutions Inc. - Ensemble Discovery Corporation For more information visit http://www.researchandmarkets.com/research/rm...flammatory
Allergic Rhinitis Therapeutics Pipeline Review 2014 - Analysis of 35 Companies & 54 Drug Profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zkn5w5/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Genentech, Inc. - Nektar Therapeutics - BioTech Tools - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - ALK-Abello A/S - Mitsubishi Tanabe Pharma Corporation - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Revance Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Array BioPharma Inc. - Stallergenes S.A. - Cytos Biotechnology AG - Allergopharma Joachim Ganzer KG - Respiratorius AB - AnaptysBio, Inc. - Oxagen Limited - Axikin Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - Laboratorios LETI S.L. - Celsus Therapeutics Plc - KAEL-GemVax Co., Ltd. - GlycoMar Limited - Fountain Biopharma Inc. - Ampio Pharmaceuticals, Inc. - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/zk...c_rhinitis
Celsus Therapeutics Plc Announces Formation of New Dermatology Scientific Advisory Board
GlobeNewswire - Mon Apr 07, 6:30AM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today the formation of a new Dermatology Scientific Advisory Board (SAB). The SAB is comprised of:
Celsus Therapeutics Plc to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief Executive Officer of Celsus, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8th, at 3:40 p.m. Eastern Daylight Time at the Westin Grand Central Hotel in New York.
Celsus Therapeutics Provides Year End 2013 Financial Results and Corporate Highlights
GlobeNewswire - Mon Mar 24, 3:05PM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, today announced its financial results and provided a review of the twelve month period ended December 31, 2013.
Celsus Therapeutics Provides Update on MRX-6 From FDA Pre-IND Meeting
GlobeNewswire - Tue Mar 11, 3:05PM CDT
-- Celsus completes Type B pre-IND meeting with FDA for MRX-6 cream in atopic dermatitis
Contact Dermatitis - Pipeline Review, H2 2013 Report
M2 - Mon Feb 17, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/hxk6vr/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2013" report to their offering. 'Contact Dermatitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Contact Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Contact Dermatitis. Scope - A snapshot of the global therapeutic scenario for Contact Dermatitis. - A review of the Contact Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Contact Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Contact Dermatitis Overview Therapeutics Development Pipeline Products for Contact Dermatitis - Overview Pipeline Products for Contact Dermatitis - Comparative Analysis Contact Dermatitis - Therapeutics under Development by Companies Contact Dermatitis - Pipeline Products Glance Clinical Stage Products Early Stage Products Contact Dermatitis - Products under Development by Companies Contact Dermatitis - Companies Involved in Therapeutics Development Contact Dermatitis - Therapeutics Assessment Drug Profiles MRX-6 - Drug Profile RTU-1096 - Drug Profile MAM-06.301 - Drug Profile AN-3485 - Drug Profile HPT-721 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned R-Tech Ueno, Ltd. Marinomed Biotechnologie GmbH Anacor Pharmaceuticals, Inc. Celsus Therapeutics Plc Hapten Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/hxk6vr/contact About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Celsus Therapeutics to Present at the 2014 BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 06, 6:30AM CST
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief Executive Officer of Celsus, will present at the 2014 BIO CEO & Investor Conference on Monday, February 10, at 4:00 p.m. Eastern Standard Time at the Waldorf Astoria in New York.
Celsus Therapeutics Announces the Closing of $9.2 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional ADSs
GlobeNewswire - Wed Feb 05, 3:05PM CST
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today the closing of its previously announced public offering of 1,533,333 American Depository Shares ("ADSs"
on the NASDAQ Capital Market at a price of $6.00 per ADS. The final number of ADSs includes the full exercise by the underwriter of its option to purchase 200,000 additional ADSs. Each ADS represents ten of the Company's ordinary shares. The gross proceeds from this offering, including from the exercise of the over-allotment option, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $9,200,000. Celsus' ADSs are listed on the NASDAQ Capital Market under the trading symbol "CLTX" and began trading there on January 31, 2014.
Celsus Therapeutics Announces Pricing of Public Offering and Listing on NASDAQ
GlobeNewswire - Thu Jan 30, 4:32PM CST
Celsus Therapeutics Plc (Nasdaq:CLTX) (formerly OTCQB:CLSXD), an emerging growth, development-stage biotech company, announced today the pricing of its public offering of 1,333,333 American Depository Shares ("ADSs" on the NASDAQ Capital Market at a price of $6.00 per ADS. Each ADS represents ten of the Company's ordinary shares. The gross proceeds from this offering, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $8,000,000. The offering is expected to close on or about February 5th, 2014, subject to customary closing conditions. Celsus also granted the underwriter a 30-day option to purchase 200,000 additional ADSs at the public offering price to cover over-allotments, if any.
Inflammatory Bowel Disease - Pipeline Review, H1 2014: 73 Companies and 135 Drugs Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/rmqbbx/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - ASKA Pharmaceutical Co., Ltd. - ActogeniX NV - Addex Therapeutics - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - AlbireoPharma - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Antibe Therapeutics, Inc. - Aquinox Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Athersys, Inc. - Atlantic Healthcare Limited - Axxam SpA - Basilea Pharmaceutica AG - BioLineRx, Ltd. - Biotec Pharmacon ASA - Boehringer Ingelheim GmbH - Catabasis Pharmaceuticals, Inc. - Celsus Therapeutics Plc - ChironWells GmbH - Complix NV - Compugen Ltd. - Creabilis SA - Delenex Therapeutics AG - Eisai Co., Ltd. - Emergent BioSolutions Inc. - Ensemble Discovery Corporation For more information visit http://www.researchandmarkets.com/research/rm...flammatory
Allergic Rhinitis Therapeutics Pipeline Review 2014 - Analysis of 35 Companies & 54 Drug Profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zkn5w5/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Genentech, Inc. - Nektar Therapeutics - BioTech Tools - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - ALK-Abello A/S - Mitsubishi Tanabe Pharma Corporation - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Revance Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Array BioPharma Inc. - Stallergenes S.A. - Cytos Biotechnology AG - Allergopharma Joachim Ganzer KG - Respiratorius AB - AnaptysBio, Inc. - Oxagen Limited - Axikin Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - Laboratorios LETI S.L. - Celsus Therapeutics Plc - KAEL-GemVax Co., Ltd. - GlycoMar Limited - Fountain Biopharma Inc. - Ampio Pharmaceuticals, Inc. - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/zk...c_rhinitis
Celsus Therapeutics Plc Announces Formation of New Dermatology Scientific Advisory Board
GlobeNewswire - Mon Apr 07, 6:30AM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today the formation of a new Dermatology Scientific Advisory Board (SAB). The SAB is comprised of:
Celsus Therapeutics Plc to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief Executive Officer of Celsus, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8th, at 3:40 p.m. Eastern Daylight Time at the Westin Grand Central Hotel in New York.
Celsus Therapeutics Provides Year End 2013 Financial Results and Corporate Highlights
GlobeNewswire - Mon Mar 24, 3:05PM CDT
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, today announced its financial results and provided a review of the twelve month period ended December 31, 2013.
Celsus Therapeutics Provides Update on MRX-6 From FDA Pre-IND Meeting
GlobeNewswire - Tue Mar 11, 3:05PM CDT
-- Celsus completes Type B pre-IND meeting with FDA for MRX-6 cream in atopic dermatitis
Contact Dermatitis - Pipeline Review, H2 2013 Report
M2 - Mon Feb 17, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/hxk6vr/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2013" report to their offering. 'Contact Dermatitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Contact Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Contact Dermatitis. Scope - A snapshot of the global therapeutic scenario for Contact Dermatitis. - A review of the Contact Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Contact Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Contact Dermatitis Overview Therapeutics Development Pipeline Products for Contact Dermatitis - Overview Pipeline Products for Contact Dermatitis - Comparative Analysis Contact Dermatitis - Therapeutics under Development by Companies Contact Dermatitis - Pipeline Products Glance Clinical Stage Products Early Stage Products Contact Dermatitis - Products under Development by Companies Contact Dermatitis - Companies Involved in Therapeutics Development Contact Dermatitis - Therapeutics Assessment Drug Profiles MRX-6 - Drug Profile RTU-1096 - Drug Profile MAM-06.301 - Drug Profile AN-3485 - Drug Profile HPT-721 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned R-Tech Ueno, Ltd. Marinomed Biotechnologie GmbH Anacor Pharmaceuticals, Inc. Celsus Therapeutics Plc Hapten Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/hxk6vr/contact About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Celsus Therapeutics to Present at the 2014 BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 06, 6:30AM CST
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief Executive Officer of Celsus, will present at the 2014 BIO CEO & Investor Conference on Monday, February 10, at 4:00 p.m. Eastern Standard Time at the Waldorf Astoria in New York.
Celsus Therapeutics Announces the Closing of $9.2 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional ADSs
GlobeNewswire - Wed Feb 05, 3:05PM CST
Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today the closing of its previously announced public offering of 1,533,333 American Depository Shares ("ADSs"
on the NASDAQ Capital Market at a price of $6.00 per ADS. The final number of ADSs includes the full exercise by the underwriter of its option to purchase 200,000 additional ADSs. Each ADS represents ten of the Company's ordinary shares. The gross proceeds from this offering, including from the exercise of the over-allotment option, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $9,200,000. Celsus' ADSs are listed on the NASDAQ Capital Market under the trading symbol "CLTX" and began trading there on January 31, 2014. Celsus Therapeutics Announces Pricing of Public Offering and Listing on NASDAQ
GlobeNewswire - Thu Jan 30, 4:32PM CST
Celsus Therapeutics Plc (Nasdaq:CLTX) (formerly OTCQB:CLSXD), an emerging growth, development-stage biotech company, announced today the pricing of its public offering of 1,333,333 American Depository Shares ("ADSs"
on the NASDAQ Capital Market at a price of $6.00 per ADS. Each ADS represents ten of the Company's ordinary shares. The gross proceeds from this offering, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $8,000,000. The offering is expected to close on or about February 5th, 2014, subject to customary closing conditions. Celsus also granted the underwriter a 30-day option to purchase 200,000 additional ADSs at the public offering price to cover over-allotments, if any. 
